peptide analogs via on resin click chemistry. In preparation.

Patent Status: U.S. Provisional Application No. 61/347,038 filed 21 May 2010 (HHS Reference No. E–130–2010/0–US–01).

Licensing Status: Available for licensing.

Licensing Contact: Whitney Hastings; 301–451–7337; *hastingw@mail.nih.gov.*

Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders

Description of Invention: The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may prevent degradation of pro-apoptotic factors permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways, has been a successful mode of treatment for such cancers. However, some patient's cancers have been found to be resistant to the drug.

Researchers at the National Institutes of Health have developed novel hydrazone and diacyl hydrazine compounds that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. These compounds preferentially target the proteasome assistant ATPase p97/VCP at a site independent of nucleotide binding. The researchers have shown that these ERAD inhibitors can induce cancer cell death and can also synergize with bortezomib in cytotoxic activity. In addition to treating diseases or disorders in which inhibition of the ERAD pathway is an effective therapy, these novel compounds may also be useful in the study of protein degradation.

Advantages:

- Development of therapies against tumors that are resistant to bortezomib.
- Use in therapies in combination with proteasome inhibitors.
- Development of immunosuppressive therapies that target the ubiquitin proteasome system.
- Studies of the mechanism of protein degradation and other biological processes that involve the p97 ATPase.
- Bioprobes to detect endoplasmic reticulum (ER) structures in live cells.

Advantages:

- Potent anti-tumor activity.
- Simpler chemical structure makes synthesis easier and more cost-effective than previous ERAD inhibitors.
- Retain activity against bortezomib-resistant cells and can synergize with bortezomib.
- Fluorescent.
- High affinity for the ER.

Development Status: Pre-clinical.

Inventors: Adrian Wiestner (NHLBI), William Trenkle (NIDDK), Yihong Ye (NIDDK) *et al.*

Relevant Publications:

1. Qiuyan Wang *et al.* ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009 Feb 17;106(7):2200–2205. [PubMed: 19164757]
2. Qiuyan Wang *et al.* The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PloS ONE 2010, in press.

Patent Status: U.S. Provisional Application No. 61/266,760 filed 04 Dec 2009 (HHS Reference No. E–291–2009/0–US–01).

Licensing Status: Available for licensing.

Licensing Contact: Surekha Vathyam, Ph.D.; 301–435–4076; *vathyams@mail.nih.gov.*

Targeted Anti-Cancer Compounds for Treating Chromosomal Instability Syndromes

Description of Invention: At $47 billion, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. There remains a significant unmet need for new therapeutics that target cancer cells while sparing normal cells. Cancer cells show higher levels of DNA damage than normal cells, and therefore rely more heavily than normal cells on DNA repair mechanisms for survival. There is a particular need for cancer therapies for cancer-prone chromosomal instability syndromes such as Ataxia Telangiectasia, Nijmegen Breakage, Bloom, and Fanconi's anemia, which result from dysfunctional DNA repair systems.

Researchers at Columbia University and the National Cancer Institute (NCI) have developed compositions and methods of useful in the treatment of cancer and in the sensitization of cancer cells to cancer therapy. The compositions target the MRE11–RAD50–NBS1 (MRN) complex, a DNA repair complex essential for sensing and responding to DNA damage.

Given the dependency of cancer cells on DNA repair systems, they are susceptible to compositions that inhibit DNA damage repair. Thus, cancers that already have one or more defects in DNA repair systems, such as those from patients with chromosomal instability syndromes, are effectively treated with the present compositions.

Applications: Development of treatments for cancer.

Development Status: Pre-clinical.

Inventors: Levy Kopelovich (NCI) *et al.*

Relevant Publication: A Dupré *et al.* A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex. Nat Chem Biol. 2008;4(2):119–125. [PubMed: 18176557]

Patent Status:

- U.S. Provisional Application No. 61/203,377 filed 22 Dec 2008 (HHS Reference No. E–154–2009/0–US–01).
- International Application No. PCT/US09/69171 filed 22 Dec 2009, which published as WO 2010/075372 on 01 Jul 2010 (HHS Reference No. E–154–2009/0–PCT–02).

Licensing Status: Available for licensing.

Licensing Contact: Patrick P. McCue, Ph.D.; 301–435–5560; *mccuepat@mail.nih.gov.*

Collaborative Research Opportunity: The National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize agents for the prevention and treatment of cancer. Please contact John Hewes, Ph.D. at 301–435–3121 or *hewesj@mail.nih.gov* for more information.

Dated: November 24, 2010.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2010–30278 Filed 12–1–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Citizenship and Immigration Services

Agency Information Collection Activities: Form I–914, Extension of a Currently Approved Information Collection; Comment Request

ACTION: 30-Day Notice of Information Collection under Review: Form I–914 and Supplements A and B, Application for T Nonimmigrant Status; Application for Immediate Family Member of T–1 Recipient; and Declaration of Law Enforcement Officer for Victim of

Trafficking in Persons; OMB Control No. 1615–0099.

The Department of Homeland Security, U.S. Citizenship and Immigration Services (USCIS) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the **Federal Register** on September 8, 2010, at 75 FR 54646, allowing for a 60-day public comment period. USCIS did not receive any comments for this information collection.

The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until January 3, 2011. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Department of Homeland Security (DHS), and to the Office of Management and Budget (OMB) USCIS Desk Officer. Comments may be submitted to: USCIS, Chief, Regulatory Products Division, 20 Massachusetts Avenue, Washington, DC 20529–2020. Comments may also be submitted to DHS via facsimile to 202–272–0997 or via e-mail at *rfs.regs@dhs.gov*, and to the OMB USCIS Desk Officer via facsimile at 202–395–5806 or via e-mail at *oira_submission@omb.eop.gov*. When submitting comments by e-mail please make sure to add OMB Control Number 1615–0099 in the subject box. Written comments and suggestions from the public and affected agencies should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

Overview of This Information Collection

(1) *Type of Information Collection:* Extension of a currently approved information collection.

(2) *Title of the Form/Collection:* Application for T Nonimmigrant Status; Supplement A: Application for Immediate Family Member of T–1 Recipient; and Supplement B: Declaration of Law Enforcement Officer for Victim of Trafficking in Persons.

(3) *Agency form number, if any, and the applicable component of the Department of Homeland Security sponsoring the collection:* Form I–914; U.S. Citizenship and Immigration Services (USCIS).

(4) *Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Individuals or Households.* Form I–914 permits victims of severe forms of trafficking and their immediate family members to demonstrate that they qualify for temporary nonimmigrant status pursuant to the Victims of Trafficking and Violence Protection Act of 2000 (VTVPA), and to receive temporary immigration benefits.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* Form I–914, 500 responses at 2.25 hours per response; Supplement A, 500 responses at 1 hour per response; Supplement B, 200 responses at .50 hours per response.

(6) *An estimate of the total public burden (in hours) associated with the collection:* 1,725 annual burden hours.

If you need a copy of the information collection instrument, please visit the Web site at: *http://www.regulations.gov*.

We may also be contacted at: USCIS, Regulatory Products Division, 20 Massachusetts Avenue, NW., Washington, DC 20529–2020; Telephone 202–272–8377.

Dated: November 24, 2010.

Sunday Aigbe,

Chief, Regulatory Products Division, U.S. Citizenship and Immigration Services, Department of Homeland Security.

[FR Doc. 2010–30150 Filed 12–1–10; 8:45 am]

BILLING CODE 9111–97–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[IDI–36712]

Notice of Proposed Withdrawal and Opportunity for Public Meeting; Idaho

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

SUMMARY: The Forest Service (FS) has filed an application with the Bureau of Land Management (BLM) requesting the Assistant Secretary of the Interior for Land and Minerals Management to withdraw 10 acres of public land adjacent to the Clearwater National Forest from mining to protect the Lenore Tree Improvement Area near Orofino, Idaho and adjacent to the Clearwater River. This notice segregates the land for up to 2 years from settlement, sale, location or entry under the United States mining laws. The land will remain open to mineral leasing and to all activities currently consistent with applicable Forest plans and those related to the exercise of valid existing rights. This parcel of land has been withdrawn for FS use since 1990 for genetic seedling testing purposes. This proposed withdrawal covers the same 10 acres that were withdrawn for FS use under Public Land Order (PLO) No. 6799, BLM Serial Number IDI–26701, published on Friday, September 14, 1990 in the **Federal Register** (55 FR 37878). Due to an administrative oversight on the part of the FS, PLO 6799 expired before an extension of the withdrawal can be processed. Therefore, the FS is requesting a new 20-year withdrawal covering the same area.

DATES: Comments and request for a public meeting must be received by March 2, 2011.

ADDRESSES: Comments and meeting requests should be sent to the Forest Supervisor, Clearwater National Forest, 12730 Highway 12, Orofino, Idaho 83544.

FOR FURTHER INFORMATION CONTACT: Laura Summers, BLM Idaho State Office, 208–373–3866 or Scott Bixler, Forest Service, (406) 329–3655.

SUPPLEMENTARY INFORMATION: The FS has filed an application to withdraw the following described public land from settlement, sale, location and entry under the United States mining laws, subject to valid existing rights:

Boise Meridian

Clearwater National Forest

T. 37 N., R. 1 W.,
Sec. 32, N½S½NW¼SW¼.